JAGX Stock Analysis: Buy, Sell, or Hold?
JAGX - Jaguar Health, Inc.
$2.47
-0.22 (-8.18%)
▼
5d:
-9.52%
30d:
-37.31%
90d:
+389.3%
HOLD
LOW Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When JAGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JAGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: JAGX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: JAGX is currently trading at $2.47, which is considered oversold relative to its 30-day fair value range of $2.80 to $3.54.
Technical Outlook: Technically, JAGX is in a uptrend. The price is currently testing key support at $2.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $262.50 (+10527.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JAGX is in a uptrend. The price is currently testing key support at $2.56. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 8.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $262.50 (+10527.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.80 -
$3.54
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.2%)
- BULLISH: Trading 10527.5% below Wall St target ($262.50)
- CAUTION: Recommendation downgraded due to -9.5% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.80 -
$3.54
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.56
Resistance Level
$3.66
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.26
Wall Street Target
$262.50
(+10527.5%)
Revenue Growth (YoY)
815.6%
Profit Margin
-115.4%
Share & Embed Analysis
Last updated: June 15, 2026 11:01 PM ET
Data refreshes hourly during market hours. Next update: 12:01 AM
Data refreshes hourly during market hours. Next update: 12:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 55 HOLD |
